Livzon Pharmaceutical Group (SHE:000513, HKG:1513) agreed to buy a 64.81% stake in Vietnam-listed Imexpharm (HOSE:IMP), which specializes in antibiotics and cardiovascular drugs, for about 1.59 billion yuan.
The stake will be purchased from SK Investment Vina III, Sunrise Kim Investment and KBA Investment, according to a Friday filing with the Shenzhen bourse.
The deal, slated to close within nine months, awaits regulatory clearances in Vietnam.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.